Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alogliptin in Pediatric Type 2 Diabetes
NCT02856113Phase 3Completed
- Sponsor
- Takeda
- Start
- Oct 2016
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 3 trial of alogliptin in type 2 diabetes mellitus (T2DM), sponsored by Takeda. Started Oct 2016; status: completed.
02
Drugs
alogliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02856113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02856113.